Concert Pharmaceuticals Company Profile (NASDAQ:CNCE)

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its quarterly earnings results on Tuesday, May, 2nd. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.06. The business earned $0.02 million during the quarter. Concert Pharmaceuticals had a negative return on equity of 55.30% and a negative net margin of 36,357.25%. View Concert Pharmaceuticals' Earnings History.

5 equities research analysts have issued 12-month target prices for Concert Pharmaceuticals' shares. Their predictions range from $20.00 to $32.00. On average, they expect Concert Pharmaceuticals' share price to reach $26.40 in the next year. View Analyst Ratings for Concert Pharmaceuticals.

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:

• 1. HC Wainwright analysts commented, "de-risked platform for drug discovery" along with a lead clinical asset for alopecia areata.Over the past five years, the company has leveraged its proprietary platform as a source for external partnerships and has had four validating partnership deals, the analyst continued. The most recent partnership related to the acquisition of CTP-656 which is under FTC review before the final close date in October.While there is "little clarity" into the review process of CTP-656, investors should believe in the "fundamental value of a deuterated potentiator to the many players still eager to assemble the best-in-class triple combo for cystic fibrosis," Fein stated.CTP-543The recent clinical hold lift of Concert's CTP-543, a deuterated ruxolitinib (a JAK1/2 inhibitor), for the treatment of adults with moderate-to-severe AA, should be viewed as the removal of an overhang and clears a path for a phase 2a readout in the bottom half of 2018, Fein also noted."We suspect that this clinical hold may [have] less to do with endogenous factors (e.g., the compound or trial itself), and more to do with exogenous factors (e.g., the evolving sphere of research around AA field and JAK inhibitor research broadly)," he wrote. "As such, we applaud management's attitude in starting an open and conciliatory dialogue with the agency early on to prevent any possible negative downstream scenarios and allow the data to speak for itself." (7/24/2017)
• 2. Aegis analysts commented, "We still anticipate the deal to close and for Concert to receive the $160 mil upfront payment." (6/12/2017)
• 3. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (5/8/2017)

Some companies that are related to Concert Pharmaceuticals include CRISPR THERAPTC (CRSP), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), Intellia Therapeutics (NTLA), Mesoblast Limited (MESO), Wave Life Sciences Ltd (WVE), ANI Pharmaceuticals (ANIP), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Agenus (AGEN), Cara Therapeutics (CARA), AC Immune SA (ACIU), Adamas Pharmaceuticals (ADMS), PDL BioPharma (PDLI), Abeona Therapeutics (ABEO), Celyad SA (CYAD), Idera Pharmaceuticals (IDRA) and Puretech Health PLC (PRTC).

Concert Pharmaceuticals' management team includes the folowing people:

• Richard H. Aldrich, Chairman of the Board, Co-Founder
• Roger D. Tung Ph.D., President, Chief Executive Officer, Co-Founder, Director
• Ryan Lynch, Principal Financial Officer, Principal Accounting Officer
• Nancy Stuart, Chief Operating Officer
• Robert Silverman Ph.D. J.D., Senior Vice President and General Counsel
• James Cassella,, Senior Vice President, chief development officer
• Christine Boisclair, Vice President - Regulatory Affairs
• Scott Weintraub, Vice President - Commercial and Product Strategy
• Thomas G. Auchincloss Jr., Director
• Ronald W. Barrett Ph.D., Director

Concert Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.33%) and Rockefeller Financial Services Inc. (0.05%). Company insiders that own Concert Pharmaceuticals stock include Nancy Stuart, Pauline Mcgowan, Robert Silverman, Roger D Tung, Ronald W Barrett, Thomas G Auchincloss and Wilfred E Jaeger. View Institutional Ownership Trends for Concert Pharmaceuticals.

Concert Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Roger D Tung and Thomas G Auchincloss. View Insider Buying and Selling for Concert Pharmaceuticals.

Shares of Concert Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Concert Pharmaceuticals stock can currently be purchased for approximately $15.50.